Injective is a blockchain platform built for finance, offering Web3 applications on what they describe as the fastest layer 1 blockchain shaping the future of finance.

Injective

Pollen is a decentralized virtual asset trading suite that offers traditional trading experiences through DeFi and virtual crypto trading. Self-described as making decentralized trading simple, safe, and accessible.

Pollen DeFi

INJECTIVE

📢 We're thrilled to announce that we have successfully completed our smart contract #security assessment for kakeru.finance—the first native stablecoin on INJECTIVE 🔒 

🔗 Full report available: https://lnkd.in/dmsD9ZyV

#audit #blockchainsecurity #security

Injective transcends the boundaries of a simple blockchain. It fosters a vibrant ecosystem brimming with innovative dApps that empower both developers and users.

Here are some standout dApps:


Trading Tools:
HelixApp - offers a clean user experience with automated spot grid bots and innovative markets, leveraging Injective's order book.


DeFi dApps:
@MitoFinance, @hydro_fi, and @Dojo_Swap - these apps allow you to swap tokens, leverage $INJ staking, and engage in yield farming.


NFT Fi:
@ProtocolTalis and @Dagoraxyz
 - these apps enhance Injective’s NFT ecosystem by introducing financial use cases for #NFTs, such as NFT lending.

#Injective is your Web3 finance one-stop shop. 
Whether it's DeFi, NFT Fi, Game Fi, or RWAs, you can trade, borrow, lend, insure, and more – all with the help of innovative dApps built on INJECTIVE.

Dive into the future of finance with Injective!

Liquid staking is now live on #BlackPanther_Fi, allowing users to stake their $INJ tokens.

With this new feature, users can effortlessly manage their staked tokens and enhance their yield.

Don't miss out on this opportunity! 


INJECTIVE

🔷 7 Day Top Coins By Price: #Ethereum Ecosystem
$100M+ Market Cap
 
1. $CET: +26.2%
2. $ALPH: +22.1%
3. $BMX: +21.1%
4. $BANANA: +20.1%
5. $OM: +18.4%
6. $KNC: +16.2%
7. $INJ: +15.9%
8. $JASMY: +14.8%
9. $AGLD: +14.6%
10. $BICO: +13.8%

📈 Source: Synopsis Solutions

CoinEx Global Alephium BitMart MANTRA Kyber Network INJECTIVE Jasmy MGT Biconomy

INJECTIVE’S ALL-NEW LAYER-3 NETWORK - WHAT WE KNOW…

- Today saw INJECTIVE and The Arbitrum Foundation collaboratively announce an all-new layer-3 network called ‘inEVM’.

- The network is built using Arbitrum’s ‘Orbit Stack’, though it has been heavily customized, creating a bespoke architecture for inEVM.

- As you may have guessed by the name, inEVM is compatible with the world-renowned Ethereum Virtual Machine (EVM) and connects Ethereum, Solana, and Cosmos, to provide a never before seen degree of interoperability.

- According to an official release from Injective…

“With inEVM, users gain access to a seamless platform connecting Ethereum, Injective and Cosmos, enabling cross-chain compatibility and fostering a more interconnected blockchain landscape. This interoperability opens up a myriad of possibilities for developers and users alike”

- In short, inEVM both provides developers access to the Ethereum ecosystem, while also maintaining the “lightning fast speeds and low fees” exhibited by Injective itself.

- inEVM will leverage $INJ as its native gas token and inEVM transactions also qualify for Injective’s well-known ‘Burn Auction’.

“As Injective continues to bridge the gap between Ethereum, Cosmos and other widely adopted L1s, including Solana, it steadfastly advances its mission in creating a more democratized financial future through decentralization”

Image: Hashim Qamar [Medium]

#AMBAGuide
Does your project struggle with managing its public appearance? 🤔 Delegate it to your supporters!

💼 Projects like INJECTIVE are almost entirely ambassador-driven! 
In 10 months, their ~280 Ambassadors created over 100,000 pieces of UGC. They also handled community management, translated all blog posts into 12 languages, and created 24 local Community X pages and 21 local Telegram chats. 📈 
There are no real alternatives to this kind of support, especially in the early stages of your project. PLUS, you can pay your ambassadors whenever is best for the business. 🎯  

⚡ We have created more than 5 successful ambassador programs and there are some alpha to share. Follow Solus Group to not miss the tips on what to do or avoid when creating your program!

Metric
Company Name	Injective	Pollen DeFi
Symbol
MSH ID	COM:INJECTIVE	ID:POLLEN
Market	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Financial Services & Finance
Industry	Blockchain and Cryptocurrency	Cryptocurrency
Country		ID
Stage		Series A
Employee Count	23
Website	injective.com	pollen.id
LinkedIn	injective
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	28.87K	91
Web Traffic Growth	0.14	-0.69
Valuation
Raised Capital	40M	5M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

INJE

COM:INJECTIVE

Injective

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue